EGFR and non-small cell lung carcinoma: Remon et al enrolled 116 pretreated advanced NSCLC patients (1 treatment‐naive), and performed NGS‐based plasma genotyping.16 In patients with previously unknown molecular profiles, two patients were treated with EGFR TKIs.